A study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10 mg) compared to the combinations of ramipril/amlodipine (10/10 mg) and aliskiren/amlodipine (300/10 mg) in patients with essential hypertension and metabolic syndrome not adequately responsive to amlodipine 10 mg

Trial Profile

A study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10 mg) compared to the combinations of ramipril/amlodipine (10/10 mg) and aliskiren/amlodipine (300/10 mg) in patients with essential hypertension and metabolic syndrome not adequately responsive to amlodipine 10 mg

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2012

At a glance

  • Drugs Aliskiren (Primary) ; Ramipril (Primary) ; Amlodipine
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms ALTO
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Apr 2012 Planned number of patients changed from 178 to 846 as reported by European Clinical Trials Database record.
    • 12 Apr 2012 Status changed from discontinued to completed as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top